Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFECT trial of baricitinib-first versus TNF inhibitor-first treat-to-target strategy in rheumatoid arthritis
NL-OMON48248Phase 4Active, not recruiting
- Sponsor
- Overige Centra
- Start
- Sep 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of baricitinib in rheumatoid arthritis (RA), sponsored by Overige Centra. Primary endpoint: ACR50 response at 12 weeks. Started Sep 2019; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON48248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48248.